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Symptom burden in inflammatory bowel disease: Rethinking conceptual and
theoretical underpinnings
Symptom control is fundamental to the nursing management of inflammatory bowel disease (IBD). However, symptom
control can be problematic for individuals with IBD, which could result in symptom burden. Symptom burden is an
evolving concept in the discipline of nursing and to date little is known about how the defining characteristics of this
concept have been applied to symptom research in IBD. In this discussion paper, the concept of symptom burden and the
theory of unpleasant symptoms are explored as a basis for understanding for symptom research in IBD. This is followed
by a critical examination of previous symptom research in IBD. Our conclusion is that there is a need to rethink conceptual
and theoretical underpinnings of symptom burden when researching IBD to take account of its defining characteristics,
namely symptom severity, frequency and duration, quality and distress. Research knowledge on these defining charac-
teristics will be important to inform nursing assessment of symptom burden in clinical practice.
Key words: ••.
INTRODUCTION
Crohn’s disease and ulcerative colitis, collectively known
as inflammatory bowel disease (IBD), are lifelong ill-
nesses. Over the last decade, the incidence and prevalence
of IBD have significantly escalated.1 There is a widespread
occurrence of IBD worldwide. Prevalence rates for ulcer-
ative colitis range from 37 to 246 cases per 100 000
persons and for Crohn’s disease range from 26 to 199
cases per 100 000, with a higher incidence of IBD in
northern Europe and America and lower incidence in
southern Europe, Asia and developing countries.2
Inflammatory bowel disease is characterized by unpre-
dictable periods of relapse and remission. Individuals
commonly experience debilitating symptoms such as
abdominal pain, diarrhoea, weight loss and rectal bleed-
ing. These symptoms can result in disruption to their daily
lives potentially imposing significant symptom burden.
Nursing assessment of problematic symptoms and the
identification of symptom burden are therefore integral to
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the chronic illness management of individuals with IBD.
Although the concept of symptom burden has been
addressed in the medical and psychological literature over
many years, only recently has it been recognized as a new
evolving concept in the discipline of nursing.3
The purpose of this paper is to examine conceptual
literature on symptom burden and its defining character-
istics. The theory of unpleasant symptoms will be
examined in terms of its similarity with characteristics
of the concept of symptom burden. Previous research
on symptom burden in IBD is then examined to deter-
mine what dimensions have been studied. Our review of
conceptual, theoretical and empirical literature is then
discussed with consideration to implications for practice
and future research.
THE CONCEPT OF SYMPTOM
BURDEN
For individuals with IBD, symptoms are a major part of
their lives and are fundamental to nursing care particularly
in the assessment stage of the nursing process. In recent
years, there has been a growing interest in exploring the
nature of symptoms resulting in the publication of con-
ceptual analyses and discussions particularly in the field of
oncology nursing. Work to date has focused mostly on the
concepts of symptom experience4,5 and symptom clusters
(measure of multiple symptoms).6–8 Symptom burden,
although related to the concepts of symptom experience
and symptom clusters, is a distinct concept.9
Guided by Rodger’s method of concept analysis,
Gapstur identified five key attributes of symptom burden:
multidimensional, dynamic, quantifiable, subjective and
physiological burden.3 As a multidimensional concept,
assessment of symptom burden needs to focus on fre-
quency, severity and distress of symptoms experienced by
individuals. Variation in any one or more of these dimen-
sions characterizes the dynamic nature of symptom
burden and this variation depends on factors such as the
stage or prognosis of disease and treatments. Symptom
burden is quantifiable therefore, permitting the measure-
ment of symptoms that are more or less burdensome for
individuals. The subjective attribute of symptom burden
indicates an individual’s awareness of and meaning
attached to change in functioning and sensation as a result
of experiencing a symptom.10,11 To assess the subjective
nature of symptom burden, it is necessary to glean the
perspectives or self-reports of the individual experiencing
the symptom;3 a point also supported by other
researchers.5 Finally, symptoms can impose an alternation
in the physical functioning of the human body thus
symptom burden can be ‘physiological’.
Gapstur’s analysis is important as it represents a begin-
ning definition of the concept of symptom burden.3
Although the analysis is mostly informed by oncology
literature, dimensions of symptom burden seem appli-
cable to illnesses other than cancer. According to Gapstur,
continued development of the concept of symptom
burden is needed.3 Although not addressed by Gapstur,3
one consideration for further advancing the concept of
symptom burden is to develop its theoretical base. As
suggested by Walker and Avant,12 a concept analysis is a
fundamental block of a theory but does not help to explain
how various components or concepts within a theory are
interrelated.
THE THEORY OF UNPLEASANT
SYMPTOMS
To date, no unified theory of symptom burden has been
reported in the nursing or allied health literature.
However, the middle-range theory of unpleasant symp-
toms developed in the mid-1990s10,11 is proposed herein as
relevant to explaining symptom burden in a complete and
insightful way for both researchers and practitioners.
According to Lenz et al.,11 the theory of unpleasant symp-
toms has the potential to integrate existing information
about a variety of symptoms. Although an unpleasant
symptom can occur in isolation, the presence of multiple
symptoms simultaneously is a more common experience
for individuals experiencing illnesses. The manifestation
of symptoms can vary in terms of intensity/severity,
degree of associated distress, timing and quality. Intensity
refers to severity and is the most frequently and easily
assessed dimension of unpleasant symptoms.13 For
example, a pain scale can measure the intensity of pain on
a scale of 0–10 with increasing scores representing
increasing severity of this symptom.
The dimension of distress is the degree to which
patients are bothered by symptoms experienced. For each
individual, this dimension is unique as it is subjective to
the meaning an individual attaches to the unpleasant
symptoms.13 The dimension of timing refers to the dura-
tion and frequency of symptoms, which can be classified as
acute or chronic. Symptoms might fluctuate in frequency
and duration over the trajectory of the disease or treat-
ment.13 The dimension of ‘quality’ refers to the manner in
which symptoms manifest and the feelings these inflict on
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individuals. Each symptom can have a number of qualita-
tive descriptors based on sensations experienced by an
individual. For example, pain can be characterized as stab-
bing, pounding, throbbing or sharp.13 These theorists have
suggested that a change in the quality of unpleasant symp-
toms as reported by an individual might signal a change in
the disease progression or disease stage. The descriptors
used in communicating the quality of unpleasant symp-
toms can vary from individual to individual.13
In addition to the central concept of ‘symptoms’, the
theory of unpleasant symptoms has two further concepts:
influencing factors and performance. Factors influencing
symptoms are conceptualized as physiological (disease,
treatment-related factors, age and gender), psychological
(e.g. mood), cognitive (e.g. level of knowledge and
coping skills) and/or situational (social and physical envi-
ronment). Performance is the outcome concept of the
theory, focusing on negative consequences of symptoms
and which has multiple dimensions in relation to func-
tional and cognitive abilities.13 With consideration to all
three concepts (symptoms, influencing factors, perfor-
mance), the theory of unpleasant symptoms is a complex
interactive model of symptom experience. However,
despite its complexity, the theorists have stated that for
both researchers and practitioners, the dimensions of
unpleasant symptoms are measurable.13
SYMPTOM BURDEN RESEARCH
IN IBD
To date, little research has been conducted on symptom
burden of individuals with IBD that takes account of con-
ceptual or theoretical underpinnings. However, studies
have investigated specific dimensions of symptom burden,
most commonly, symptom severity using a growing
number of disease activity indices specific to Crohn’s dis-
ease14 or ulcerative colitis.15 Individuals with Crohn’s
disease have been found to experience greater symptom
severity than patients with ulcerative colitis.16 However,
irrespective of disease type (Crohn’s disease or ulcerative
colitis), individuals with IBD have been found to experi-
ence greater symptom severity than healthy age-matched
controls.17 Disease activity indices as measures of
symptom severity are of limited practical value to nursing
assessment of individuals with IBD however, because they
require clinical input of signs, laboratory markers includ-
ing histology reports. Disease activity indices are also
limited in the number of symptoms assessed, often focus-
ing only on the classic symptoms associated with Crohn’s
disease or ulcerative colitis. A further limitation is that
symptom severity as disease activity is but one dimension
of symptom burden. These points were addressed by
researchers who developed a Survey-based Crohn’s
disease Activity measure of symptoms (general well-
being, abdominal pain, number of loose stools per day).18
However, these researchers raised concern that this index
might not accurately capture disease burden.
The ‘frequency’ of symptoms as a dimension of
symptom burden has been assessed in patients with IBD to
lesser extent than symptom severity. Not surprisingly,
symptoms have been shown to occur more frequently
during periods of relapse compared with remission.19,20
For example, a Finnish study (n = 2424) revealed that
between 34% and 41% of patients can experience weekly
flare-up of symptoms for ulcerative colitis and Crohn’s
disease, respectively.21 The duration or timing of symp-
toms as distinct from the frequency of occurrence13 is a
further consideration in researching symptom burden.
There is little known to date however on the duration of
symptoms experienced by patients with IBD.
Researchers have varied in the number of IBD-related
symptoms assessed ranging from as few as three22 to as
many as 28.19 Focusing on too few symptoms or just those
representing classic features of ulcerative colitis (abdomi-
nal pain, diarrhoea and rectal bleeding) or Crohn’s disease
(abdominal pain, diarrhoea and weight loss) runs the risk
of missing important data relevant to clinical assessment
of symptom frequency. Interestingly, data from patient
focus groups have shown that the majority of the most
frequent symptoms experienced were ‘novel’ (e.g. stool
mucus, loud bowel sounds, flatulence). These data point
to the existence of multiple symptoms or ‘symptom clus-
ters’, which could also contribute to symptom burden3,13
but have received little attention in IBD research to date.
Symptoms of high intensity, frequency and prolonged
duration might contribute to significant distress for indi-
viduals with IBD, particularly during acute exacerbations.
Pain has been described as one of the most distressing
symptoms of living with ulcerative colitis.23 Distress asso-
ciated with bowel symptoms has consistently been
reported in studies, specifically relating to loss of bowel
control, uncontrollable bowel sounds, bowel urgency,
incontinence and unpleasant odours.24–26 Frequent bowel
motions and associated odours have been described as
‘rotten stuff’ that ‘stinks’.24 These quality descriptors
illustrate the subjective nature of symptoms and the
feelings that symptoms can inflict on individuals, as
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suggested by Lenz and Pugh13 in the theory of unpleasant
symptoms.
IMPLICATIONS FOR RESEARCH
As evident from the empirical literature reviewed, many
researchers have studied the problem of symptoms in
individuals with IBD. Research has been conducted
mostly on symptom severity and to a lesser extent on
symptom frequency and distress. Collectively, these areas
represent some key characteristics of symptom burden as
conceptually defined by Gapstur,3 therefore capturing in
part its multidimensional perspective. The areas of
symptom burden previously studied are also consistent
with some key characteristics of the theory of unpleasant
symptoms.10,11,13 However, previous research on the
study of symptom burden specific to IBD has been piece-
meal, because as already noted, one dimension has been
privileged in research over others, namely severity. For a
comprehensive measurement of symptom burden that is
conceptual and theoretically based, future research on
IBD needs to take account of all of its dimensions or
characteristics.
Although there has been little attempt to measure all
dimensions of the concept of symptom burden in indi-
viduals with IBD, the potential for this is evident in studies
on symptom burden in other chronic illnesses. For
example, the concept has been measured in individuals
with cystic fibrosis,27 heart failure28 and cancer.29
Symptom burden has been measured using various instru-
ments including the Memorial Symptom Assessment Scale
(MSAS), the Memorial Symptom Assessment Scale Short
Form and the Edmonton Symptom Assessment System.
All scales are reliable and valid. However, the MSAS
seems particularly useful as it incorporates most dimen-
sions of symptom burden, namely the frequency, severity
and distress associated with symptoms. In the MSAS, the
dimension of frequency measures 24 symptoms using a
four-point Likert scale. A larger number of 32 symptoms
are measured for severity and distress using a four-point
Likert scale and a five-point Likert scale, respectively.19
Although the dimension of timing (duration) of symptoms
is not a subscale of the MSAS, this could be added to the
scale and then tested for reliability.
Although the MSAS was originally developed to
measure symptom burden in individuals with cancer,19 the
measure can be adapted to include disease-specific symp-
toms such as rectal bleeding, flatulence, bowel urgency
and more symptoms relevant to IBD. Furthermore, the
MSAS measures symptom burden in relation to physical
and psychological symptoms. Psychological symptoms
included in the measure are worrying, feeling irritable,
feeling nervous and feeling sad. The inclusion of psycho-
logical symptoms is important because it draws attention
to symptom burden being psychological as well as physi-
cal. The MSAS as a measure of symptom burden could
therefore address the current imbalance in IBD research,
which has predominantly focused on physical symptoms.
Although studies have measured depression and anxiety in
individuals with IBD,30–32 data on individual symptoms or
the level of burden associated with these symptoms
cannot be extracted from this research. There is a need to
further understand the psychological burden of symptoms
because as indicated in qualitative studies on individuals
with IBD, they can experience anger, fear and worry.24,25
Future qualitative research into symptom experiences of
individuals with IBD is needed to add to the current body
of knowledge about the psychological impact of symp-
toms. This research would be important to identifying
problematic symptoms that could be included in the mea-
surement of symptom burden. However, qualitative
research has merit, not just for the purpose of informing
measurement, but also for capturing the subjective
meaning that individuals attach to their symptom burden
experiences.
IMPLICATIONS FOR PRACTICE
Symptom burden is relevant to nursing practice particu-
larly in relation to clinical assessment. Dimensions of the
concept of symptom burden3 and the theory of unpleasant
symptoms10,11,13 are proposed herein with consideration to
physical and psychological symptoms as a framework for
clinical assessment with reference to the frequency, sever-
ity, distress, duration and quality of symptoms in indi-
viduals with IBD.
The dynamic nature of symptom burden3 prompts the
need for ongoing assessment of problematic symptoms,
which is especially important in the case of IBD for which
symptom control is a key goal of nursing management.
Research has shown that symptoms are more problematic
in disease relapse state compared with remission.20
A further consideration in the clinical assessment of
symptom burden in patients with IBD is to incorporate
multiple symptoms. It is possible that multiple symptoms
impose greater symptom burden. Individuals with IBD
typically experience the cardinal symptoms of IBD,
namely diarrhoea, abdominal pain, rectal bleeding and
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weight loss.22 However, some research prompted the
need to broaden the number of symptoms assessed to
including irritable bowel syndrome-like symptoms such as
abdominal distension, mucus, bowel urgency and strain-
ing.33 A focus on physical symptoms only however would
be too narrow a focus in the assessment of symptom
burden as it is known individuals with IBD can experience
psychological symptoms such as fear, worry and anger.
Nurses also need to take account of symptom burden as
a subjective experience, which can vary from one patient
to the next. In essence, symptom burden is the product of
a specific interpretation of a symptom experience. There-
fore, in practice, differences can be expected between
individuals regarding how they experience the level of
severity, frequency, duration, distress and quality of
symptoms. Given the subjective nature of symptom
burden, it is important that nurses understand the mean-
ings that individuals attach to the symptom experiences so
that care plans to manage symptoms are developed and
implemented in ways that are relevant and meaningful to
individuals’ unique experiences.
Although assessment of symptom burden is paramount
to the nursing care of individuals with IBD, there is a lack
of reliable and valid clinical assessment tools available to
nurses. As noted from the empirical literature, clinical
indices do exist but are limited because they address a
small number of symptoms and focus on symptom sever-
ity only. Clinical guidelines to support nursing assessment
of symptom burden are also lacking. These deficits in
current practice reinforce the need for further research, as
recommended earlier in this paper. Research that is
informed by conceptual and theoretical underpinning of
symptom burden has the potential to enhance the practice
of nursing through its application to the assessment of
symptom burden in individuals with IBD.
CONCLUSION
Knowing what is meant by a concept in terms of its defin-
ing attributes or dimensions is important to researching a
concept and to applying a concept to practice situations.
For example, a researcher investigating symptom burden
in individuals with IBD would need to know how this
concept is defined and operationalized for the purpose of
measurement. Likewise, a nurse practitioner would need
to know the dimensions of symptom burden for the
purpose of symptom assessment of individuals with IBD.
In this paper, we set out to examine conceptual and
theoretical literature of relevance to symptom burden as a
basis for examining the focus of studies conducted to date
on the level of burden among individuals with IBD. Pre-
vious symptom research in IBD is limited to addressing
burden primarily within the context of symptom severity.
Researchers need to rethink conceptual and theoretical
underpinnings of symptom burden in IBD with consider-
ation to broadening the scope of dimensions for measure-
ment. This research and its application to practice could
be guided by conceptual literature on symptom burden
and the theory of unpleasant symptoms, as described in
this paper.
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